CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
is intended to assess the ability of AZD3427 to reduce pulmonary vascular resistance (PVR) after 24 weeks of treatment in participants with heart...
Phase 2
Sevilla, Spain and 63 other locations
tomography (OCT) findings indicative of vulnerable plaque, in patients with ST-elevation myocardial infarction (STEMI) and multivessel disease...
Sevilla, Spain and 41 other locations
Evaluation of TAVR using the NAVITOR valve in a Global Investigation.
Sevilla, Spain and 37 other locations
The researchers are doing this study to look whether the type 2 diabetes medicine, semaglutide, has a positive effect on heart disease...
Phase 3
Sevilla, Spain and 467 other locations
reduction of cardiovascular death (generally meaning death due to disease of the heart or blood vessels) and total Heart F...
Phase 3
Sevilla, Spain and 663 other locations
This study will look at the effects of CagriSema on cardiovascular events (for example heart attack and stroke) in people living with cardio...
Phase 3
Sevilla, Spain and 521 other locations
This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults wi...
Phase 3
Sevilla, Andalucía, Spain and 851 other locations
The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the cl...
Phase 3
Sevilla, Spain and 173 other locations
of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) ...
Phase 3
Sevilla, Spain and 70 other locations
of these proteins is thought to damage the kidneys and the heart. By lowering their stimulation, finerenone reduces the risk of kidney disease...
Phase 3
Castilleja de la Cuesta, Spain and 80 other locations
Clinical trials
Research sites
Resources
Legal